Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

Antonio Russo, Viviana Bazan, Beranek, Fujimori, Hall, Clarke, Angelis, Croke, Glaesener, Goeij, Malik, Ho, Muller, Fox, Zhang, Cunningham, Faber, Laurent-Puig, Cruickshank, SunOmura, Andreyev, Ward, Losi, O'Donoghue, Piris, Rognum, Halter, Quirke, Ho, Benhattar, Cruickshank, Thebo, Krtolica, Valavanis, Lövig, Fahd Al-Mulla, Jullian, Bubb, Meling, Breivik, Urosevic, Troungos, Rapallo, Pricolo, Dix, Zietz, Jandik, Snary, Clausen, Giaretti, Dillon, Font, Ohkusa, Barry Iacopetta, Hoffmann, H-S. Goh, Olschwang, Gaudernack, Lees, Senagore, Rabes, Benamouzig, Oates, Wadler, Pauly, Rafael Rosell, Hawkins, Wilkinson, Yuen, Andersen, Azuma, Arends, Norman, Morton, Bell, Costa, Ono, Tanaka, Young, Wang, Smith, Lee, Finkelstein, Walsh

Risultato della ricerca: Article

651 Citazioni (Scopus)

Abstract

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in- colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.
Lingua originaleEnglish
pagine (da-a)692-696
Numero di pagine5
RivistaBritish Journal of Cancer
Volume85
Stato di pubblicazionePublished - 2001

Fingerprint

Colorectal Neoplasms
Mutation
Survival
Codon
Valine
Neoplasms
Glycine
Databases
Rectum
Adenoma
Colon
Multivariate Analysis
Genotype
Research Personnel
Genome
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. / Russo, Antonio; Bazan, Viviana; Beranek; Fujimori; Hall; Clarke; Angelis; Croke; Glaesener; Goeij; Malik; Ho; Muller; Fox; Zhang; Cunningham; Faber; Laurent-Puig; Cruickshank; Sun; Omura; Andreyev; Ward; Losi; O'Donoghue; Piris; Rognum; Halter; Quirke; Ho; Benhattar; Cruickshank; Thebo; Krtolica; Valavanis; Lövig; Al-Mulla, Fahd; Jullian; Bubb; Meling; Breivik; Urosevic; Troungos; Rapallo; Pricolo; Dix; Zietz; Jandik; Snary; Clausen; Giaretti; Dillon; Font; Ohkusa; Iacopetta, Barry; Hoffmann; Goh, H-S.; Olschwang; Gaudernack; Lees; Senagore; Rabes; Benamouzig; Oates; Wadler; Pauly; Rosell, Rafael; Hawkins; Wilkinson; Yuen; Andersen; Azuma; Arends; Norman; Morton; Bell; Costa; Ono; Tanaka; Young; Wang; Smith; Lee; Finkelstein; Walsh.

In: British Journal of Cancer, Vol. 85, 2001, pag. 692-696.

Risultato della ricerca: Article

Russo, A, Bazan, V, Beranek, Fujimori, Hall, Clarke, Angelis, Croke, Glaesener, Goeij, Malik, Ho, Muller, Fox, Zhang, Cunningham, Faber, Laurent-Puig, Cruickshank, Sun, Omura, Andreyev, Ward, Losi, O'Donoghue, Piris, Rognum, Halter, Quirke, Ho, Benhattar, Cruickshank, Thebo, Krtolica, Valavanis, Lövig, Al-Mulla, F, Jullian, Bubb, Meling, Breivik, Urosevic, Troungos, Rapallo, Pricolo, Dix, Zietz, Jandik, Snary, Clausen, Giaretti, Dillon, Font, Ohkusa, Iacopetta, B, Hoffmann, Goh, H-S, Olschwang, Gaudernack, Lees, Senagore, Rabes, Benamouzig, Oates, Wadler, Pauly, Rosell, R, Hawkins, Wilkinson, Yuen, Andersen, Azuma, Arends, Norman, Morton, Bell, Costa, Ono, Tanaka, Young, Wang, Smith, Lee, Finkelstein & Walsh 2001, 'Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study', British Journal of Cancer, vol. 85, pagg. 692-696.
Russo, Antonio ; Bazan, Viviana ; Beranek ; Fujimori ; Hall ; Clarke ; Angelis ; Croke ; Glaesener ; Goeij ; Malik ; Ho ; Muller ; Fox ; Zhang ; Cunningham ; Faber ; Laurent-Puig ; Cruickshank ; Sun ; Omura ; Andreyev ; Ward ; Losi ; O'Donoghue ; Piris ; Rognum ; Halter ; Quirke ; Ho ; Benhattar ; Cruickshank ; Thebo ; Krtolica ; Valavanis ; Lövig ; Al-Mulla, Fahd ; Jullian ; Bubb ; Meling ; Breivik ; Urosevic ; Troungos ; Rapallo ; Pricolo ; Dix ; Zietz ; Jandik ; Snary ; Clausen ; Giaretti ; Dillon ; Font ; Ohkusa ; Iacopetta, Barry ; Hoffmann ; Goh, H-S. ; Olschwang ; Gaudernack ; Lees ; Senagore ; Rabes ; Benamouzig ; Oates ; Wadler ; Pauly ; Rosell, Rafael ; Hawkins ; Wilkinson ; Yuen ; Andersen ; Azuma ; Arends ; Norman ; Morton ; Bell ; Costa ; Ono ; Tanaka ; Young ; Wang ; Smith ; Lee ; Finkelstein ; Walsh. / Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. In: British Journal of Cancer. 2001 ; Vol. 85. pagg. 692-696.
@article{44542961f682453b893c304877108439,
title = "Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study",
abstract = "Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in- colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6{\%} of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.",
author = "Antonio Russo and Viviana Bazan and Beranek and Fujimori and Hall and Clarke and Angelis and Croke and Glaesener and Goeij and Malik and Ho and Muller and Fox and Zhang and Cunningham and Faber and Laurent-Puig and Cruickshank and Sun and Omura and Andreyev and Ward and Losi and O'Donoghue and Piris and Rognum and Halter and Quirke and Ho and Benhattar and Cruickshank and Thebo and Krtolica and Valavanis and L{\"o}vig and Fahd Al-Mulla and Jullian and Bubb and Meling and Breivik and Urosevic and Troungos and Rapallo and Pricolo and Dix and Zietz and Jandik and Snary and Clausen and Giaretti and Dillon and Font and Ohkusa and Barry Iacopetta and Hoffmann and H-S. Goh and Olschwang and Gaudernack and Lees and Senagore and Rabes and Benamouzig and Oates and Wadler and Pauly and Rafael Rosell and Hawkins and Wilkinson and Yuen and Andersen and Azuma and Arends and Norman and Morton and Bell and Costa and Ono and Tanaka and Young and Wang and Smith and Lee and Finkelstein and Walsh",
year = "2001",
language = "English",
volume = "85",
pages = "692--696",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

AU - Russo, Antonio

AU - Bazan, Viviana

AU - Beranek, null

AU - Fujimori, null

AU - Hall, null

AU - Clarke, null

AU - Angelis, null

AU - Croke, null

AU - Glaesener, null

AU - Goeij, null

AU - Malik, null

AU - Ho, null

AU - Muller, null

AU - Fox, null

AU - Zhang, null

AU - Cunningham, null

AU - Faber, null

AU - Laurent-Puig, null

AU - Cruickshank, null

AU - Sun, null

AU - Omura, null

AU - Andreyev, null

AU - Ward, null

AU - Losi, null

AU - O'Donoghue, null

AU - Piris, null

AU - Rognum, null

AU - Halter, null

AU - Quirke, null

AU - Ho, null

AU - Benhattar, null

AU - Cruickshank, null

AU - Thebo, null

AU - Krtolica, null

AU - Valavanis, null

AU - Lövig, null

AU - Al-Mulla, Fahd

AU - Jullian, null

AU - Bubb, null

AU - Meling, null

AU - Breivik, null

AU - Urosevic, null

AU - Troungos, null

AU - Rapallo, null

AU - Pricolo, null

AU - Dix, null

AU - Zietz, null

AU - Jandik, null

AU - Snary, null

AU - Clausen, null

AU - Giaretti, null

AU - Dillon, null

AU - Font, null

AU - Ohkusa, null

AU - Iacopetta, Barry

AU - Hoffmann, null

AU - Goh, H-S.

AU - Olschwang, null

AU - Gaudernack, null

AU - Lees, null

AU - Senagore, null

AU - Rabes, null

AU - Benamouzig, null

AU - Oates, null

AU - Wadler, null

AU - Pauly, null

AU - Rosell, Rafael

AU - Hawkins, null

AU - Wilkinson, null

AU - Yuen, null

AU - Andersen, null

AU - Azuma, null

AU - Arends, null

AU - Norman, null

AU - Morton, null

AU - Bell, null

AU - Costa, null

AU - Ono, null

AU - Tanaka, null

AU - Young, null

AU - Wang, null

AU - Smith, null

AU - Lee, null

AU - Finkelstein, null

AU - Walsh, null

PY - 2001

Y1 - 2001

N2 - Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in- colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.

AB - Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in- colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.

UR - http://hdl.handle.net/10447/76337

M3 - Article

VL - 85

SP - 692

EP - 696

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -